.
Objective:This study aims to examine the impact of ear, nose, and throat (ENT) surgeons' involvement on intraoperative costs and operating room (OR) times for retrosigmoid craniotomies using time-driven activity-based costing (TDABC). Design:A retrospective, single-center analysis was conducted. TDABC methodology was utilized to calculate total intraoperative costs. Multiple linear regression analysis was performed to assess the independent effect of ENT surgeons' involvement on surgical costs and OR time. Setting:All procedures were performed at the Thomas Jefferson University Hospital and affiliated sites between 2017 and 2022. Participants:About 255 patients underwent retrosigmoid craniotomy (166 neurosurgery only, 89 with ENT surgeons' involvement). Main Outcome Measures:Main outcome measures include total intraoperative costs calculated using TDABC methodology, OR time, supply costs, and personnel costs. Results:Inclusion of ENT surgeons was significantly associated with increased total costs (B = $4,082 ± $1,015, p < 0.001) and OR time (B = 135 ± 38 minutes, p < 0.001). The mean total cost of neurosurgery-only cases was $7,538 ± $3,977, compared with $14,217 ± $3,485 for multidisciplinary cases. Personnel costs were the primary driver of this increase, with no significant difference in supply costs between groups. Conclusion:While ENT collaboration can enhance outcomes in select cases, such as those involving vestibular schwannomas, its routine inclusion may not be cost-effective. Our study demonstrates the marginal cost of ENT collaboration for retrosigmoid craniotomies. Future studies may build on our costing framework by integrating outcomes with costs to determine the true cost-effectiveness of cross-specialty collaboration.
INTRODUCTION: Sarcoidosis is a rare systemic inflammatory disease affecting the lungs, while non-small cell lung cancer (NSCLC) is more common and the most prevalent type of lung cancer. Relationship between these diseases is unclear, however studies suggest a shared inflammatory pathway. Determining whether sarcoidosis is a precursor or consequence of NSCLC remains under active research. The following case highlights the challenges in diagnosis and treatment in a patient with both diseases due to similar presentation and vastly different treatments. CASE REPORT: A 79-year-old female, diagnosed with biopsy-proven sarcoidosis in 1999, presented to the pulmonology clinic with dyspnea. After achieving remission with prednisone in 2003, she experienced recurring symptoms in 2024, prompting a repeat CT scan that revealed abnormal airspace disease in the LUL. A PET/CT scan showed a LUL 2.2 cm irregular mass with increased metabolic activity (SUV 3.3), as well as diffuse bilateral hilar, mediastinal and subcarinal lymphadenopathy (SUV >2.5), suggestive of possible sarcoid recurrence, versus new malignancy. An elevated ACE level of 117, in conjunction with normal ionized calcium levels, was supportive of the diagnosis of sarcoidosis. Further investigation, including robotic bronchoscopy, EBUS with biopsy and FNA of the lymph nodes, revealed adenocarcinoma of pulmonary origin with a predominantly acinar pattern. Both adenocarcinoma and sarcoidosis were considered as possible concurrent diagnoses. Surgical resection confirmed a stage IA3 (pT1c, pN0, M0) NSCLC, consistent with an invasive acinar adenocarcinoma that exhibited both papillary and lepidic features. Notably, non-caseating granulomas were also identified within the surgical specimen (Figure 1). The case was classified as stage IA3 under the 8th edition staging guidelines. The patient was initiated on a daily dose of 40 mg prednisone, and pending tumor markers considering adjuvant chemotherapy for her stage IA3 lung cancer. DISCUSSION: Several studies indicate that sarcoidosis incidence is higher in oncology patients compared to the general population, although overall prevalence remains low. With similar manifestations, the coexistence of sarcoidosis and NSCLC presents a challenge. While some studies suggest an association between sarcoidosis and chronic inflammation and an increased risk of lung cancer, the exact nature of this relationship remains unclear. Treatment involves corticosteroids for sarcoidosis, in conjunction with adjuvant chemotherapy for the malignancy. This case report highlights the uncommon coexistence of sarcoidosis and NSCLC, emphasizing the need for vigilant clinical assessment, comprehensive radiological evaluation, and accurate pathological diagnosis to ensure appropriate management.
Introduction: T2DM and HTN are the most common comorbidities that are associated with increased risk for patients with COVID-19 and ARDS. However, the relationship of T2DM and HTN individually on ARDS outcomes remains unclear with conflicting data.1 We aim to investigate the association of T2DM and HTN on mortality outcomes in patients with COVID and non-COVID ARDS. Methods: We conducted a systematic review investigating the relationship between T2DM, HTN and mortality outcomes in studies evaluating patients with ARDS after 2000. A literature search was performed using PubMed, Embase, CINAHL, Web of Science, and Cochrane Central to screen for ARDS, T2DM and HTN. Outcomes included 30-day, 60-day, 90-day, 180-day, 1-year, hospital, and ICU mortality. Comparisons were made between COVID and non-COVID ARDS. Results: Of the 12,754 studies screened, 22 met the inclusion criteria. T2DM was associated with a significantly increased 90-day mortality (OR 1.73, 95% CI 1.50-1.99), but was not significantly different for other mortality outcomes including 28/30-day, 60-day, hospital, or ICU mortality. In COVID ARDS, T2DM was significantly associated with increased 28/30-day (OR 4.21, 95% CI 2.98-5.94), 90-day (OR 1.73, 95% CI 1.5-1.99), and hospital (OR 1.37, 95% CI 1.04-1.82) mortality, but not ICU mortality (OR 1.07 95%CI 0.31-3.63). In non-COVID ARDS, T2DM was similarly associated with significantly increased 60-day (OR 1.19, 95% CI 1.01-1.39) and ICU mortality (OR 40.50, 95% CI 5.81-282.32), but no significant differences were found in other mortality outcomes including 28/30-day or hospital mortality. HTN was associated with significantly increased 28/30-day (OR 1.49, 95% CI 1.01-2.21) and 90-day (OR 1.46, 95% CI 1.28-1.66) mortality, but not in-hospital or ICU mortality. Similar findings were seen for HTN in COVID ARDS. For the association of HTN and non-COVID ARDS, no difference was seen for hospital mortality, and only one study was found that measured ICU mortality showing increased risk, but with a large confidence interval. Several outcomes have not been studied for the association between HTN and non-COVID ARDS including 28/30-day, 60-day, and 90-day mortality. Conclusions: In this systematic review and meta-analysis, T2DM and HTN were associated with increased mortality at several time points in both COVID and non-COVID ARDS. Data on HTN and non-COVID ARDS are severely lacking with a majority of studies evaluating HTN being done only in COVID ARDS.